jcp conference-coverage

Conference Coverage

Videos

Clinical Decision Support in Cancer Care: Why the Patient’s Voice Matters

01/24/2024

Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.

Mary E. Cooley, PhD, RN, FAAN,...

01/24/2024

Journal of Clinical Pathways

Videos

Expanding Access to Care Through Academic-Community Cancer Care Collaboration

01/23/2024

Harlan Levine , MD;

Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.

Harlan Levine, MD, highlights...

01/23/2024

Journal of Clinical Pathways

Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre

Videos

Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer

01/20/2024

Jeanne Tie , MBChB, MD;

Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.

Professor Jeanne Tie, MBChB,...

01/20/2024

Oncology

Conference Coverage

Significance of ctDNA Clearance Following Adjuvant Chemotherapy Among Patients with Radically Resected Colorectal Cancer

01/20/2024

Allison Casey ;

According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...

According to updated results...

01/20/2024

Oncology

Conference Coverage

Role of ctDNA to Guide Adjuvant Chemotherapy Use for Patients With Colon Cancer

01/20/2024

Allison Casey ;

In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.

In the phase 2/3 COBRA study no...

01/20/2024

Oncology

Videos

Outcomes of Men With High-Risk, Biochemically Recurrent Prostate Cancer Who Discontinued Enzalutamide Monotherapy in the EMBARK Study

01/18/2024

Neal Shore , MD, FACS;

Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.

Neal Shore, MD, FACS, discusses...

01/18/2024

Journal of Clinical Pathways

Conference Coverage

Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape

01/08/2024

Bijal D. Shah , MD;

Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.

Bijal D. Shah, MD, shares the...

01/08/2024

Oncology

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

Douglas Tremblay , MD;

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Conference Coverage

The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study

12/08/2023

Grace Taylor , MS, MA;

A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.

A study by Raajit K. Rampal, MD,...

12/08/2023

Journal of Clinical Pathways

Conference Coverage

Key Factors Influencing Survival Rates in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

12/07/2023

Grace Taylor , MS, MA;

A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

A study by Helen Ajufo, MD, MS,...

12/07/2023

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products